NLST
NETLIST Loses Three Federal Circuit Appeals Against Micron on Same Day
The Federal Circuit affirmed PTAB rulings invalidating claims of five Netlist memory patents challenged by Micron, including one precedential decision.
Jamie Sulivan
PSNY
POLESTAR Posts $842M Half-Year Loss as Revenue Slips 4.4%
The EV maker cut its net loss by 29% in H1 2026, but adjusted EBITDA worsened to a loss of $521 million while deliveries were roughly flat.
CPB
CAMPBELL'S Cuts Dividend 36% and Guides FY27 EPS Down as Much as 24%
Q4 adjusted EPS fell 37% to $0.39, the quarterly payout drops to $0.25, and Campbell's targets $500 million in cost savings by fiscal 2030.
CIEN
CIENA Revenue Jumps 37% to $1.67B as AI Drives Optical Demand
Ciena posted record fiscal Q3 revenue of $1.67 billion and adjusted EPS of $2.11, and raised its full-year revenue outlook to $6.42 billion.
APGE
APOGEE THERAPEUTICS Buyout Closes as Shares Head for Delisting
An 8-K filing shows Apogee Therapeutics has completed a change-of-control transaction, replaced its board and recapitalized to just 1,000 shares.
ESTC
ELASTIC Founder Shay Banon Sells $44.5M in Shares Over Three Days
Elastic's CTO and co-founder disposed of about 476,000 ordinary shares between August 31 and September 2, cutting his stake to roughly 1.58 million shares.
AUGO
Aura Minerals Director Sells $10.4 Million of Shares in Open Market
A Form 4 shows director Bruno Sousa Mauad sold 127,500 Aura Minerals shares at $81.20 apiece on Aug. 31, cutting his stake by more than 40%.
CRWD
CrowdStrike Co-Founder Kurtz and Director Gandhi Sell $8.8M in Stock
Two CrowdStrike insiders sold a combined 40,000 Class A shares on Aug. 31 and Sept. 1 at prices between roughly $213 and $234.
NESR
NESR CEO Sherif Foda Sells $3.5M in Stock, Gifts 675,000 Shares
National Energy Services Reunited's chief executive sold 100,000 ordinary shares at $35.00 and transferred another 675,000 shares as a gift.
RVMD
FDA Approves Rasonque, First RAS Inhibitor for Metastatic Pancreatic Cancer
The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.
ROIV
FDA Approves Lisraya, First Oral Drug for Dermatomyositis in Adults
The FDA has cleared Lisraya (brepocitinib) tablets, the first oral therapy specifically indicated for adults with dermatomyositis.
PTGX
FDA Approves Mimrylo (Rusfertide), First Hepcidin Mimetic for Polycythemia Vera
The FDA has cleared Mimrylo (rusfertide) for adults with polycythemia vera, calling it the first drug of its kind for the rare blood disorder.